Ellex is committed to helping you better diagnose, manage and treat a wide range of visual problems and eye diseases. Whether you are involved in the treatment and diagnosis of cataract, glaucoma or retinal disease, Ellex has a solution for your practice, and for your patients.
Offering superior energy control, a sharp-edged aiming beam and the fastest firing rate at 3 shots per second, Ellex’s proprietary SLT technology allows you to visualize the TM in greater detail, and to perform procedures faster and with improved accuracy.
YAG laser vitreolysis offers a simple outpatient-based treatment for vitreous opacities and strands. Highly effective, it has a low complication rate and offers a high degree of patient satisfaction. Featuring perfectly coaxial illumination and ultra-low energy optical breakdown, Ultra Q Reflex™ is ideally suited to the treatment of floaters.
The tough demands of today’s new-generation intraocular lenses (IOLs) require an ever-increasing level of accuracy during YAG surgery. For this reason, Ellex YAG lasers feature state-of-the-art technology designed to achieve precise optical breakdown at the lowest energy levels possible.
Ellex solid-state photocoagulators provide safe, predictable and consistent energy delivery through a true, continuous-wave laser beam. Offering superior energy distribution from beginning to end of exposure, and across the full diameter of the treatment spot, each system delivers consistently better performance in the treatment of retinal disease.
Pattern Scanning Photocoagulation
Unlike conventional photocoagulation, pattern scanning photocoagulation uses millisecond pulse durations, which limit the potential for damage to surrounding tissue. The result is targeted burns with minimal collateral damage to surrounding tissue.
Ultrasound is one of the most fundamental diagnostic tools in ophthalmology. Even in an era of high-tech OCT scanning and digital imaging, ultrasound is the only means to obtain a crucial view of the posterior segment when there is a dense cataract or vitreous hemorrhage in the eye.
Achieving the desired therapeutic effect whilst avoiding the coagulative damage that is associated with ALT, SLT is now seen as a viable alternative to medications in patients with newly diagnosed glaucoma. Visit the Education Center to access whitepapers, presentations, webinars and much more.
The pressure damage of glaucoma causes a gradual blurring of vision and, if left untreated, can result in total, irreversible blindness. SLT is a simple, yet highly effective laser procedure that reduces the intraocular pressure associated with glaucoma. Gentle and painless, SLT causes no damage to the eye – and takes just five minutes in your doctor’s office.
Vitreous Strands and Opacities (Floaters)
If you suffer from vitreous strands and opacities (commonly referred to as “eye floaters”), then you are already familiar with the frustrating visual disturbance caused by these cobweb and cloud-like shadows. A pain-free, non-invasive laser procedure, vitreolysis can provide much-needed relief from your eye floaters – and help you take back your quality of vision.
Age-Related Macular Degeneration (AMD)
A chronic eye disease, AMD is caused by damage to the eye’s macula and can result in vision loss in the central field of vision, including blurred central vision or a blind spot. Early detection is crucial. Detecting changes early through regular check-ups with your optometrist or ophthalmologist can help to slow the progression of AMD.
Diabetic Eye Disease
High blood sugar levels can damage blood vessels in the retina. This damage is referred to as Diabetic Retinopathy. If untreated over the long-term, Diabetic Retinopathy can cause visual impairment and blindness. In order to preserve vision and prevent progression of Diabetic Retinopathy, it is important to take control of your blood sugar levels, blood pressure, and blood cholesterol.
SLT. The Gentle Alternative for Glaucoma
SLT is a gentle laser therapy, which triggers a natural healing response in the eye to reduce the intraocular pressure associated with glaucoma. It effectively lowers eye pressure in the majority of patients, but the length of time that pressure remains low depends on many factors, including: age and type of glaucoma.
Don’t Let Eye Floaters Cloud Your Vision
Also known as floater laser treatment, vitreolysis is a non-invasive, pain-free procedure that can eliminate the visual disturbance caused by floaters. It is performed in your ophthalmologist’s office and typically takes 20-60 minutes per treatment session.
Over the years, Ellex has evolved from a small scientific laser company to a global leader in ophthalmic laser technology. Our steady expansion includes local sales and service support offices in North America, Japan, Europe and Australia and a network of distribution partners in more than 100 countries.
27 February 2014
Ellex today announced its financial results for the six months ended 31 December 2013.
26 February 2014
26 February 2014 Ellex Secures CE Mark for 2RT in Treatment of Early Stage Age-Related Macular Degeneration (AMD) CE Mark for 2RT for laser treatment of early stage AMD secured This world-first treatment now available for limited roll out to key clinical sites in Europe, Australia, New Zealand, and in several South East Asian, Middle Eastern and South American countries Adelaide, Australia, 24 February 2014 – Ellex Medical Lasers Limited (ASX:ELX), a pioneer in medical technologies for the diagnosis and treatment of eye disease, today announced that it has secured a CE Mark (Conformité Européenne) for its proprietary Retinal Rejuvenation Therapy (2RT™) laser treatment of early Age-Related Macular Degeneration (AMD). The leading cause of blindness in the developed world, AMD is a chronic eye disease that can result in vision loss in the central field of vision, including blurred central vision or a blind spot. There are no other approved treatments for the early form of AMD. Current tre
30 January 2014
Ellex announced that it expects to report a profit before tax of approximately $650,000 for the six months ended 31 December 2013. This result will be a material increase in the profit before tax of $59,000 reported for the six months ended 31st December 2012.
View Share Price
Note: Prices are delayed by at least 20 minutes and are sourced from the Australian Stock Exchange. Retrieving price information indicates your acceptance of the conditions.